Women's Health

GLP-1 Side Effects in Women: What the Trials Report (2026)

By the US Health Digest editorial team · Updated July 21, 2026

The side-effect story of GLP-1 weight-loss medication is dominated by the gut: in the pivotal STEP 1 trial of semaglutide, gastrointestinal events — nausea and diarrhea most of all — were the most frequently reported side effects, typically mild-to-moderate and transient, and 4.5% of participants on semaglutide stopped treatment because of them, versus 0.8% on placebo. Rarer but more serious risks exist, which is exactly why a real prescriber screens for them — and why pregnancy is a hard stop, not a judgment call.

Most participants in the major weight-loss trials were women, so the data below is unusually relevant to the audience actually taking these drugs. Here is what the published evidence reports, what prescribers screen for, and when symptoms turn urgent.

The GI-dominant profile: what most women actually experience

In STEP 1, the 68-week trial behind semaglutide's weight-loss approval, gastrointestinal events were the most frequent side effects: nausea and diarrhea led the list, with constipation and vomiting also reported. The trial characterized these as typically transient and mild-to-moderate in severity — they tend to cluster around the weeks when the dose is being stepped up, and to settle as the body adjusts to each new level.

The number worth remembering: 4.5% of the semaglutide group discontinued treatment because of gastrointestinal events (59 participants), against 0.8% on placebo (5 participants). That cuts both ways: the large majority got through the GI phase without quitting, but the rate was more than five times the placebo rate — the side effects were real enough that roughly one participant in twenty-two decided they were not worth it. Anyone selling these medications as side-effect-free is not describing the trial record.

The picture is not unique to semaglutide. In SURMOUNT-1, the pivotal trial of tirzepatide, the side-effect profile was broadly similar: gastrointestinal events again dominated, again mostly mild-to-moderate, again concentrated during dose escalation. If you are weighing the two drugs, our Wegovy vs Zepbound comparison covers how the efficacy data differs; on tolerability, the trials tell a similar story.

Side effects at a glance

The rarer risks a prescriber screens for

Beyond the GI phase, there are uncommon but serious risks that shape who should not take these medications and what gets monitored during treatment. Pancreatitis and gallbladder disease are the two a legitimate intake asks about directly — a history of either changes the prescribing conversation. We deliberately do not attach incidence numbers here: these are screening and monitoring topics, and the responsible framing is that your prescriber should raise them, not that you should calculate odds from a headline.

This screening step is also one reason the FDA has raised concerns about unapproved and compounded GLP-1 products, where its stated worries include dosing errors — a hazard that lands directly on the side-effect profile, since GI symptoms are dose-related. A vial with ambiguous concentration is a titration plan you cannot actually follow.

The pregnancy hard stop

For women, one rule sits above the rest: GLP-1 medications are not used in pregnancy. Prescribers treat pregnancy, breastfeeding, and near-term pregnancy plans as a stop condition, not a dose-adjustment question. A prescriber who does not ask about pregnancy plans before prescribing — and again at renewals — is skipping the single most important screening question for this audience. If you become pregnant or begin trying to conceive during treatment, contact your prescriber promptly rather than deciding alone how to stop.

Managing the GI phase — what clinicians commonly advise

None of the following is medical advice; it is what is commonly clinician-advised, and each item is a conversation to have with your own prescriber:

• Slower titration. Holding a dose level longer before stepping up is a standard response to rough GI weeks — which is why access to a prescriber between shipments matters, as we detail in how GLP-1 telehealth actually works.
• Smaller, slower meals. These drugs slow stomach emptying; large or fatty meals tend to collide with that.
• Hydration. Particularly relevant when diarrhea or vomiting occur, since fluid loss compounds the problem.

When to contact a clinician urgently

Transient nausea during a dose increase is the expected pattern. Severe or persistent abdominal pain (especially radiating to the back), persistent vomiting, inability to keep fluids down, signs of dehydration, or yellowing of skin or eyes are not — those warrant prompt medical contact, not a wait for the next scheduled check-in. Suspected side effects from any GLP-1 product can also be reported to the FDA's MedWatch program, which is how post-approval safety signals get counted.

For the efficacy side of the ledger, see our review of semaglutide trial results in women; for eligibility and prescriber-conversation questions, our GLP-1 FAQ for women is the place to start.